Strategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Office of Assistant Secretary for Preparedness and Response (ASPR), BARDA has awarded a hybrid cost reimbursement/fixed price contract for Strategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP). This acquisition focuses on the advanced development, FDA licensure, procurement, shipping, and vendor managed inventory (VMI) storage of a MARV monovalent vaccine. The award date was May 7, 2026.
Scope of Work
This contract enables BARDA to utilize Project BioShield funds for critical activities related to a Marburg virus (MARV) monovalent vaccine. Key objectives include:
- Advanced development of the MARV vaccine.
- Achieving US Food and Drug Administration (FDA) licensure.
- Procurement of the vaccine.
- Managing shipping logistics.
- Establishing vendor managed inventory (VMI) storage solutions.
Contract Details
- Type: Hybrid Cost Reimbursement/Fixed Price
- Awarding Agency: BARDA - ASPR / DAAPPO / BARDA DCMA (under Health And Human Services)
- Product/Service Code: 6505 (Drugs And Biologicals)
- Place of Performance: Washington, DC, United States
- Award Date: May 7, 2026
Rationale for Contract Type
The hybrid contract structure was chosen because the agency's requirements could not be sufficiently defined to allow for a purely fixed-price contract, reflecting the complex and evolving nature of advanced vaccine development and procurement.